Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Blood Test Device Proven in the Field

By LabMedica International staff writers
Posted on 02 Jul 2014
A blood testing platform has been introduced that accommodates test strips for a wide variety of conditions from celiac disease, allergy through to infectious diseases such as malaria and human immunodeficiency virus (HIV).

The blood test device AtomoRapid HIV has been awarded Best in Show, and the winner of the In Vitro Diagnostics Category, at the Medical Design Excellence Awards (MDEA), held June 11, 2014, in New York (NY, USA). More...


The company that manufactures the AtomoRapid device is Atomo Diagnostics (Sydney, Australia) is an award-winning based healthcare company with a focus on product development and usability. Atomo develops and commercializes next generation solutions that address unmet user needs in the diagnostic industry.

The AtomoRapid HIV test uses a World Health Organization (WHO; Geneva, Switzerland) prequalified, antibody test for the detection of HIV 1&2 in human whole blood, serum or plasma. It is a highly sensitive screening test that performs well when deployed in the field. Given its ease of use and simplicity, AtomoRapid HIV has the ability to materially improve both the uptake and reliability of HIV testing in the community and at home. AtomoRapid HIV test is currently available for sale in several African countries from their South Africa office. AtomoRapid Malaria, the second test to market, will be available in the 3rd Quarter of 2014 and they plan to introduce additional tests in the coming 18 months.

John Kelly, B.Eng, MSc, EMBA, Founder and CEO of Atomo Diagnostics, said, “Clinical performance of standard test kits is proven in the laboratory, but serious concerns have been raised about in-field performance. This is down to their complex nature, requiring multiple components for the procedure offering resulting in errors, which in turn creates false diagnosis. For a disease such as HIV, this can have significant impact not only on the individual, but the community too.”

Related Links:

Medical Design Excellence Awards 
Atomo Diagnostics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gastrointestinal Panel
Xpert® GI Panel
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The approach uses in-house pathology tests and streamlined access to specialists to shorten the diagnostic pathway for children with immune conditions. (Image Credit: iStock)

Streamlined Genetic Testing Speeds Pediatric Immune Disorder Diagnosis

Children with genetic immune conditions can develop life-threatening illness, unusual infections, or autoimmune problems before the underlying cause is identified. More than 500 of these rare disorders... Read more

Immunology

view channel
Image: Acute myeloid leukemia is the first of several disease areas the collaborators plan to pursue together as part of efforts to advance precision diagnostics (Image Credit: Adobe Stock)

Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.